Skip Navigation

Your Environment. Your Health.

Selected Publications

Intracellular Regulation Group

  1. Miller DS, Bauer B and Hartz AMS. Modulation of P-glycoprotein at the blood-brain barrier: Opportunities to improve CNS pharmacotherapy. Pharmacol. Rev., 60:196-209, 2008.
  2. Hawkins BT, Sykes DB and Miller DS. Rapid, reversible modulation of blood-brain barrier p-glycoprotein transport activity by vascular endothelial growth factor. J. Neurosci., 30:1417-25, 2010. [Abstract (http://www.ncbi.nlm.nih.gov/pubmed/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=20107068) ]
  3. Hartz AMS, Miller DS and Bauer B. Restoring blood-brain barrier P-glycoprotein reduces brain Amyloidβ in an Alzheimer's disease model. Mol Pharm, 77:715-23, 2010. [Abstract (http://www.ncbi.nlm.nih.gov/pubmed/20101004) ]
  4. Miller DS. Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier. Trends in Pharmacological Sciences, 31:246-54, 2010. [Abstract (http://www.ncbi.nlm.nih.gov/pubmed/20417575) ]
  5. Hartz AMS, Miller DS and Bauer B. 17-β-Estradiol: A Powerful Modulator of Blood-Brain Barrier BCRP Activity. J Cerebral Blood Flow Metab, 30:1742-55, 2010. [Abstract (http://www.ncbi.nlm.nih.gov/pubmed/20216549) ]
  6. Hartz AMS, Madole E, Miller DS and Bauer B. Estrogen receptor β signaling through PTEN/PI3K/Akt/GSK3 downregulates blood-brain barrier BCRP. JPET, 334:467-76, 2010. [Abstract (http://www.ncbi.nlm.nih.gov/pubmed/20460386) ]
  7. Rigor RR, Hawkins BT and Miller DS. Activation of PKC isoform βI at the blood-brain barrier rapidly decreases P-glycoprotein activity and enhances drug delivery to the brain. J Cerebral Blood Flow Metab, 30:1373-83, 2010. [Abstract (http://www.ncbi.nlm.nih.gov/pubmed/20197783) ]
  8. Hawkins BT, Rigor RR and Miller DS. Rapid loss of blood-brain barrier P-glycoprotein activity through transporter internalization demonstrated using a novel in situ protection assay. J Cerebral Blood Flow Metab, 30:1593-7, 2010. [Abstract (http://www.ncbi.nlm.nih.gov/pubmed/20628400) ]
  9. Wang X, Sykes DB, and Miller DS. Constitutive androstane receptor-mediated upregulation of ATP-driven xenobiotic efflux transporters at the blood-brain barrier. Mol Pharm, 78:376-83, 2010. [Abstract (http://www.ncbi.nlm.nih.gov/pubmed/20547735) ]
  10. Zhang W, Phillips K, Wielgus A, Liu J, Albertini A, Zucca F, Faust R, Quian Y, Miller DS, Chignell C, Jackson-Lewis V, Przedborski S, Joset D, Loike J, Hong J-S, Sulzer D, Zecca L. Neuromelanin activates microglia and induces substantia nigra neuron death. Implications for progression of Parkinson's disease. Neurotox Res., 19:63-72, 2011. [Abstract (http://www.ncbi.nlm.nih.gov/pubmed/19957214) ]
  11. Wang X, Hawkins BT, and Miller DS. Aryl hydrocabon receptor-mediated upregulation of ATP-driven xenobiotic efflux transporters at the blood-brain barrier. FASEB J. 25:644-652, 2011. [Abstract (http://www.ncbi.nlm.nih.gov/pubmed?term=FASEB%20J.%2025%3A644-652%2C%202011) ]
  12. Zhang D, Hu X, Qian L, Chen SH, Zhou H, Wilson B, Miller DS, Hong JS. Microglial MAC1 receptor and PI3K are essential in mediating β-amyloid peptide-induced microglial activation and subsequent neurotoxicity. J Neuroinflammation 8:3, 2011. [Abstract (http://www.ncbi.nlm.nih.gov/pubmed/21232086) ]
  13. Wang X, Hawkins BT, and Miller DS. Activating PKCβ1 at the blood-brain barrier reverses induction of P-glycoprotein activity by dioxin and restores drug delivery to the CNS. J Cerebral Blood Flow Metab, 31:1371-5, 2011.
  14. Namanja HA, Emmert D, Davis DA, Campos C, Miller DS, Hrycyna CA, Chmielewski J. Toward eradicating HIV reservoirs in the brain: Inhibiting P-glycoprotein at the blood-brain barrier with prodrug abacavir dimers. J Am Chem Soc 134:2976-80, 2012.
  15. Campos CR, Schroeter C, Wang, X, Miller DS. ABC transporter function and regulation at the blood-spinal cord barrier. J Cerebral Blood Flow Metab, 32:1559-66, 2012.
  16. Jablonski MR, Jacob DA, Campos CR, Miller DS, Maragakis NJ, Pasinelli P, Trotti D. Selective increase of two ABC transporters at the blood-spinal cord barrier suggests disease-driven pharmacoresistance in ALS. Neurobiology of Disease, 47:194-200, 2012.
  17. Cannon RE, Peart JC, Hawkins BT, Campos CR, Miller DS. Targeting sphingolipid signaling at the blood-brain barrier reduces basal P-glycoprotein activity and improves drug delivery to the brain. Proc Natl Acad Sci, 109:15930-5, 2012.
  18. Block ML, Elder A, Auten RL, Bilbo SD, Chen H, Chen JC, Cory-Slechta DA, Costa D, Diaz-Sanchez D, Dorman DC, Gold DR, Gray K, Jeng HA, Kaufman JD, Kleinman MT, Kirshner A, Lawler C, Miller DS, Nadadur SS, Ritz B, Semmens EO, Tonelli LH, Veronesi B, Wright RO, Wright RJ. The outdoor air pollution and brain health workshop. Neurotoxicology 33:972-84, 2012.
  19. Durk MR, Chan G, Campos, C, Peart J, Chow E, Lee E, Cannon R, Bendayan R, Miller DS, Pang SK. 1α,25-Dihydroxyvitamin D3-Liganded vitamin D receptor increases expression and transport activity of P-glycoprotein in isolated rat brain capillaries and human and rat brain microvessel endothelial cells. J. Neurochem. 123:944-53, 2012.
  20. Cartwright TA, Campos CR, Cannon RE, Miller DS. Mrp1 is essential for sphingolipid signaling to P-glycoprotein in mouse blood-brain and blood-spinal cord barriers. J Cerebral Blood Flow Metab. In press.
  21. Wang X, Cabrera RM, Li Y, Miller DS, Finnell RH. Functional regulation of P-glycoprotein at the blood-brain barrier in proton-coupled folate transporter (PCFT) mutant mice. FASEB J, in press.
  22. Cannon RE and Miller DS. Signaling pathways that regulate basal ABC transporter activity at the blood-brain barrier. Current Pharmaceutical Design, in press.

Back to Top